Literature DB >> 28127259

Frequency of Gleason score 7 to 10 in 5100 elderly prostate cancer patients.

Navin Shah1, Vladimir Ioffe2.   

Abstract

Men 70 to 80 years of age are known to have an increased incidence of high-grade (Gleason sum score [GSS] 7-10) prostate cancer. We determined the frequency of highgrade prostate cancer among men 70 to 80 years old in our practice. We retrospectively reviewed our 5100 prostate cancer patients who are 70 to 80 years old and who opted for radiation therapy (external radiation, brachytherapy, or combination). Data were gathered on race, prostate-specific antigen value, digital rectal examination (DRE) results, and GSS. Patients were further subdivided by age in two categories, those 70 to 75 years and 76 to 80 years, and also by time period: 2006-2010 and 2011-2015. In patients 70 to 75 years, 1426 patients had a GSS of 6 (41%) and 2042 patients had a GSS of 7 to 10 (59%). In patients 76 to 80 years old, 553 had a GSS of 6 (34%) and 1079 had a GSS of 7 to 10 (66%). In 1432 patients with an abnormal DRE result, the GSS was 6 in 376 (26%) and GSS was 7 to 10 in 1059 (74%). Based on analysis of 5100 prostate cancer patients in our practice, we determined that 61% of patients age 70 to 80 have a high-grade prostate cancer, as do 59% of patients age 70 to 75 years, and 66% of patients between age 76 and 80 years. Because biopsy underestimates the grade in GSS 6 patients by 50%, the actual frequency is approximately 80%. In patients with prostate cancer who had an abnormal DRE result, 74% had a GSS of 7 to 10-approximately 85% when accounting for biopsy under-grading.

Entities:  

Keywords:  Age; Gleason score; Prostate cancer

Year:  2016        PMID: 28127259      PMCID: PMC5260947          DOI: 10.3909/riu0732

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  20 in total

1.  Early detection of prostate cancer: AUA Guideline.

Authors:  H Ballentine Carter; Peter C Albertsen; Michael J Barry; Ruth Etzioni; Stephen J Freedland; Kirsten Lynn Greene; Lars Holmberg; Philip Kantoff; Badrinath R Konety; Mohammad Hassan Murad; David F Penson; Anthony L Zietman
Journal:  J Urol       Date:  2013-05-06       Impact factor: 7.450

2.  Expected population impacts of discontinued prostate-specific antigen screening.

Authors:  Roman Gulati; Alex Tsodikov; Ruth Etzioni; Rachel A Hunter-Merrill; John L Gore; Angela B Mariotto; Matthew R Cooperberg
Journal:  Cancer       Date:  2014-07-25       Impact factor: 6.860

3.  Prostate Cancer Grading: A Decade After the 2005 Modified Gleason Grading System.

Authors:  Oleksandr N Kryvenko; Jonathan I Epstein
Journal:  Arch Pathol Lab Med       Date:  2016-01-12       Impact factor: 5.534

4.  Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence.

Authors:  Adam I Cole; Todd M Morgan; Daniel E Spratt; Ganesh S Palapattu; Chang He; Scott A Tomlins; Alon Z Weizer; Felix Y Feng; Angela Wu; Javed Siddiqui; Arul M Chinnaiyan; Jeffrey S Montgomery; Lakshmi P Kunju; David C Miller; Brent K Hollenbeck; John T Wei; Rohit Mehra
Journal:  J Urol       Date:  2016-02-23       Impact factor: 7.450

5.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

6.  Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.

Authors:  Annelies Vellekoop; Stacy Loeb; Yasin Folkvaljon; Pär Stattin
Journal:  J Urol       Date:  2013-09-23       Impact factor: 7.450

7.  National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.

Authors:  Michael W Drazer; Dezheng Huo; Scott E Eggener
Journal:  J Clin Oncol       Date:  2015-06-08       Impact factor: 44.544

8.  Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.

Authors:  Jason A Efstathiou; Ming-Hui Chen; William J Catalona; David G McLeod; Peter R Carroll; Judd W Moul; Kimberly A Roehl; Anthony V D'Amico
Journal:  Urology       Date:  2006-08       Impact factor: 2.649

9.  A comparative analysis of prostate cancer pre-treatment characteristics stratified by age.

Authors:  Navin Shah; Vladimir Ioffe; Anish Kapur
Journal:  Can J Urol       Date:  2014-04       Impact factor: 1.344

10.  Radical prostatectomy in men aged >or=70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram.

Authors:  Lee Richstone; Fernando J Bianco; Hiral H Shah; Michael W Kattan; James A Eastham; Peter T Scardino; Douglas S Scherr
Journal:  BJU Int       Date:  2008-03       Impact factor: 5.588

View more
  3 in total

1.  Prostate biopsy characteristics: A comparison between pre- and post- United States Preventive Service Task Force Prostate Cancer Screening Guidelines of 2012.

Authors:  Navin Shah; Thomas Huebner; Vladimir Ioffe; Richard Hum
Journal:  Rev Urol       Date:  2017

2.  Prostate Biopsy Characteristics: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Guidelines.

Authors:  Navin Shah; Vladimir Ioffe; Thomas Huebner; Ivelina Hristova
Journal:  Rev Urol       Date:  2018

3.  Identification of Plasma Glycosphingolipids as Potential Biomarkers for Prostate Cancer (PCa) Status.

Authors:  Ashley J Snider; Michael C Seeds; Laurel Johnstone; Justin M Snider; Brian Hallmark; Rahul Dutta; Cristina Moraga Franco; John S Parks; Jeannette T Bensen; Corey D Broeckling; James L Mohler; Gary J Smith; Elizabeth T H Fontham; Hui-Kuan Lin; William Bresette; Susan Sergeant; Floyd H Chilton
Journal:  Biomolecules       Date:  2020-09-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.